Topic: Apthera Inc.
Despite issuing seventeen apparently positive news releases since the beginning of 2011, trading charts show little to cheer about regarding an...
Posted on 04/14/11 at 7:08am by Franklin Price . RXi Pharmaceuticals Corporation (Nasdaq: RXII ) developing and commercializing innovative...
The early-stage RXi Pharmaceuticals (RXII) pulled off what could become a surprising coup last week when it announced a merger with privately-held...
Let's kick off this week's Biotech Stock Mailbag with talk of new drug launches. RMB77 asks, "Do you have any indication about how well Avanir...
Apthera, Inc. announced the optimized dose and schedule for its lead drug, NeuVax, in treating early-stage breast cancer patients to be used in Phase III clinical trials. The optimal dose and schedule of NeuVax was established as one milligram of E75 peptide ...
